Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Catalent delays filing of annual report
05:33pm, Friday, 30'th Aug 2024
Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up
12:51pm, Friday, 30'th Aug 2024
CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.
Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates
09:46am, Thursday, 29'th Aug 2024
Catalent (CTLT) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.09 per share a year ago.
Catalent beats revenue estimates ahead of deal close with Novo Nordisk parent
08:07am, Thursday, 29'th Aug 2024
Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and manufactures cell and gene therapies.
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 06'th Aug 2024
Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two companies is the best option for those looking
UTHR vs. CTLT: Which Stock Is the Better Value Option?
12:46pm, Wednesday, 17'th Jul 2024
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking for underv
Catalent (CTLT) Expands Its Facility Capabilities in Germany
01:31pm, Tuesday, 16'th Jul 2024
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.
UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?
12:46pm, Tuesday, 16'th Jul 2024
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two stocks offers value investors a better bang for
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
02:00am, Tuesday, 16'th Jul 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion
UTHR or CTLT: Which Is the Better Value Stock Right Now?
12:46pm, Monday, 15'th Jul 2024
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT). But which of these two companies is the best option for those looking
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
12:36pm, Friday, 07'th Jun 2024
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
Catalent stockholders approve deal with Novo Holdings
09:21am, Wednesday, 29'th May 2024
Catalent said on Wednesday its stockholders have voted to approve its deal with Novo Holdings, the parent company of Novo Nordisk.
Catalent Stockholders Approve Transaction with Novo Holdings
09:07am, Wednesday, 29'th May 2024
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its
Surely Wines Appoints Brandon Joldersma as New CEO
09:00am, Wednesday, 29'th May 2024
AUSTIN, Texas--(BUSINESS WIRE)--Surely Wines, a trailblazer in the premium non-alcoholic wine space, is pleased to announce the appointment of Brandon Joldersma as the company's new Chief Executive Of
